0
0
In a recent address at the 2024 American College of Physicians Internal Medicine conference, Dr. Ellie Grossman shed light on the complex landscape of using cannabinoids for medical purposes. While uncertainty shrouds their efficacy for most medical conditions, Dr. Grossman, an esteemed figure at Harvard Medical School and Cambridge Health Alliance, pointed to three indications where data leans towards effectiveness.
Neuropathic pain, chemotherapy-induced nausea or vomiting, and spasticity in multiple sclerosis patients are the three conditions where cannabinoids show promise, according to Dr. Grossman. However, she highlighted the persistent dearth of high-quality research in the field, attributing this scarcity to various factors including the predominance of synthetic products in studies and the disparity between study methodologies and real-world usage.
Chronic pain emerges as a significant driver for medical cannabis use, yet Dr. Grossman cautioned against overstating its benefits. While some studies suggest potential benefits outweigh harms for chronic neuropathic pain, the evidence remains inconclusive. Moreover, hopes that cannabis could aid in combating opioid addiction were dashed by recent findings indicating no discernible impact on opioid overdose rates.
Additionally, doubts linger regarding cannabis’s efficacy in improving sleep, with Dr. Grossman emphasizing that positive outcomes primarily manifest in individuals with chronic pain. Despite potential benefits, the short-term risks associated with cannabis, including sedation and dizziness, are well-documented, prompting a cautious approach to prescribing.
Moreover, concerns arise regarding the long-term effects of cannabis, with existing evidence largely derived from recreational use scenarios. Dr. Grossman urged clinicians to consider potential interactions when patients concurrently use cannabis with other controlled substances, emphasizing the importance of open dialogue to ensure patient safety.
In conclusion, while cannabinoids hold promise for specific medical conditions, uncertainties persist regarding their broader utility and potential harms. Dr. Grossman’s insights underscore the need for further rigorous research and thoughtful clinical consideration when navigating the complex landscape of medical cannabis.
